What reviews for Wegovy actually tell you (and what they don't)

The biggest myth: five-star reviews tell you what Wegovy will do for you

It's tempting to treat a wall of positive reviews as a personal prediction. Someone posts that they lost three stone in six months, feels great, barely notices the injection, and it's easy to read that as a likely outcome. The problem is selection bias. People who have dramatic results post. People who stopped after two weeks of nausea, or who lost a more modest amount, are far less visible online.

What cuts through that bias is a controlled trial. The STEP 1 study, published in the New England Journal of Medicine, randomised nearly 2,000 adults without diabetes to either semaglutide 2.4mg or placebo over 68 weeks, alongside lifestyle support. Average weight loss was around 15% in the active group. That figure includes slow responders, people who had difficult side effects, and people who titrated cautiously. It is, by definition, more representative than any review thread. Patient accounts add texture; trial data adds honesty. You need both, but you need to weight them correctly.

NICE appraised this evidence base when recommending semaglutide for use in specialist NHS weight management services, their technology appraisal TA875 is the formal UK verdict on whether the medicine earns its place. Reviews didn't inform that; the systematic evidence did.

What patient accounts do capture well

Dismiss reviews entirely and you miss something clinically useful. Across thousands of accounts, certain patterns repeat so consistently that they align with what the trials measured: a noticeable drop in appetite that many people describe as the first real shift, gastrointestinal effects that are loudest in weeks one to four and after each dose increase, and a plateau that arrives for most people somewhere in the maintenance phase.

The nausea story is worth reading about before you start. Many people describe it as manageable if they eat smaller portions and avoid very fatty or very sweet foods, particularly on injection days. That practical knowledge doesn't live in a SmPC. A question our prescribers hear regularly is whether the side effects mean something is wrong, and patient accounts, combined with the NHS guidance on semaglutide, make it clear that mild-to-moderate GI symptoms in the early weeks are expected, not alarming.

For practical tips on getting the most from the treatment once you're on it, the Wegovy tips page pulls together evidence-based guidance on diet, activity and injection technique. That's a better source than unmoderated forum threads, where advice ranges from excellent to dangerous.

Reviews mentioning price and sourcing: why those deserve extra scepticism

A particular subset of reviews is worth treating with real caution: accounts praising a very cheap source, a discount code, or a seller on social media. Wegovy is a prescription-only medicine. In the UK, the only legal route to it is a prescription following a clinical assessment by a qualified prescriber. The MHRA has warned publicly and repeatedly about counterfeit weight-loss pens sold online, including some containing insulin rather than semaglutide, with documented hospitalisations.

Any seller offering semaglutide without a prescription, or at prices far below the market range, warrants immediate scepticism. If you've seen discount codes for Wegovy promoted online, the safety section there explains why those are a red flag rather than a deal. For a prescription medicine, price is the wrong lens. The right questions are about clinical oversight, pharmacy registration and supply chain, not who's running the cheapest promotion this week.

You can check whether any online pharmacy is properly registered in a few seconds using the GPhC pharmacy register. It's a public search tool and takes less time than reading a review thread. Worth doing before you order from anyone.

How clinical assessment fills the gap reviews leave

Even the most thorough, honest patient review can't tell you whether Wegovy is right for you. That depends on your BMI, your existing health conditions, your current medicines (particularly if you use oral contraceptives, where tirzepatide and semaglutide compare differently on interaction profiles), and a range of factors a prescriber is trained to weigh. Reviews are written after the fact by people who were deemed clinically suitable. They don't show you the people who weren't.

The age and eligibility criteria for Wegovy are worth reading if you're trying to understand whether you'd qualify. The licensed threshold is BMI 30 or above, or 27-plus with a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the whole picture, not just a number on a scales app.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. A real clinician reads your answers the same day. If treatment is clinically appropriate, it's dispensed from our GPhC-registered pharmacy and sent out with free next-working-day tracked delivery. The cost of Wegovy through a private pharmacy is worth understanding separately, because what a legitimate price includes matters as much as the headline figure. If you'd like to explore whether Wegovy is suitable for you, start your free consultation and a prescriber will review your details the same day.